Skip to main content
. 2019 Apr 23;12:39. doi: 10.1186/s13045-019-0729-2

Table 5.

BCR-ABL1 KD mutations that influence the selection of second- or third-generation TKIs

T315I Ponatinib
F317L/V/I/C, T315A Nilotinib, bosutinib* (or ponatinib if the patient failed or was unable to tolerate first and second-generation TKIs)
V299L Nilotinib (or ponatinib if the patient failed or was unable to tolerate first and second-generation TKIs)
Y253H, E255V/K, F359V/I/C Dasatinib, bosutinib* (or ponatinib if the patient failed or was unable to tolerate first and second-generation TKIs)

*There is very limited data available on mutations associated with clinical resistance to bosutinib in vivo. Some in vitro data suggested that the E255K and, to a lesser extent, the E255V, might be poorly sensitive to bosutinib [120]